ScreenerHero

CANF Can-Fite BioPharma Ltd.

AMEX · US · Healthcare · Biotechnology · canfite.com
2.100USD-1.87%Mkt Cap: 6.37M $P/E: —

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap6.37M USD
Enterprise Value-2.41M USD
Revenue (TTM)405.00K USD
Gross Profit405.00K USD
Net Income (TTM)-9.83M USD
Revenue/Share0.28 USD
Last Price2.100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.35
PEG—
EV/EBITDA0.25
EV/Revenue-5.95
P/S16.02
P/B0.94
EPS (TTM)-13.23
EPS (Forward)-0.91
52W Range
2.1000% of range13.40
52W High13.40 USD
52W Low2.100 USD
Profitability
Gross Margin100.00%
Oper. Margin-2316.83%
EBITDA Margin0.00%
Profit Margin-2426.67%
ROE-175.75%
ROA-103.30%
Growth
Revenue Growth0.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.95M USD
CapEx (TTM)2.00K USD
FCF Margin-1377.65%
FCF Yield-87.64%
Net Debt-6.99M USD
Net Debt/EBITDA0.72
Balance Sheet
Debt/Equity0.01
Current Ratio3.60
Quick Ratio3.17
Book Value/Sh2.27 USD
Cash/Share3.29 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 10, 2019
Splits
Last Split1:20
Split DateJan 5, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.000 USD
Upside (mean)+281.0%
Target Range8.000 USD – 8.000 USD
# Analysts1
Ownership
Shares Out.3.03M
Float2.14M
Insiders0.00%
Institutions1.66%
Short Interest
Short Ratio0.1d
Short % Float1.97%
Short % Out.1.96%
Shares Short59.38K
Short (prev mo.)61.81K
Technical
SMA 502.819 (-25.5%)
SMA 2003.445 (-39.0%)
Beta-0.02
S&P 52W Chg16.45%
Avg Vol (30d)713.87K
Avg Vol (10d)36.76K
Technical Indicators
RSI (14)27.9
MACD-0.2680
MACD Signal-0.2707
MACD Hist.+0.0027
BB Upper3.364 USD
BB Middle2.426 USD
BB Lower1.487 USD
BB Width77.40%
ATR (14)0.1445 USD
Vol Ratio (20d)0.04x